EUCTR2004-004356-39-IT进行中（未招募）1 期
Gemtuzumab Ozogamicin (GO) monotherapy versus standard supportive care for previously untreated AML in elderly patients who are not eligible for intensive chemotherapy: a randomized phase II/III trial (AML-19)of the EORTC-LG and GIMEMA-ALWP - GIMEMA AML19 (EORTC 06031)
E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER0 个研究点目标入组 259 人开始时间: 2005年5月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 259
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Gemtuzumab ozogamicin (GO) combined with standard intensive chemotherapy versus standard intensive chemotherapy alone for induction/consolidation in patients 61-75 years old with previously untreated AML: a randomized phase III trial (AML- 17) of the EORTC-LG and the GIMEMA-ALWP.EUCTR2005-001347-37-ITG.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
Unknown
2 期
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaLeukemiaNCT00091234European Organisation for Research and Treatment of Cancer - EORTC279
已完成
2 期
A study of gemtuzumab ozogamicin in combination with G-CSF after CAG or MEC (CA-G-GO therapy or MEC-G-GO therapy) for relapsed or refractory acute myeloid leukemia.Acute Myeloid LeukemiaJPRN-UMIN000027522Wakayama Medical University20
进行中（未招募）
1 期
Phase II Study on Gemtuzumab Ozogamicin in Combination with All-trans-Retinoic Acid, high-dose Cytarabine and Mitoxantrone in Patients with primary refractory acute myeloid leukemia [GO-A-HAM] - GO-A-HAMEUCTR2004-003739-30-ATniversitätsklinikum Ulm / University Clinical Center Ulm84
已完成
不适用
Phase I study of Gemtuzumab Ozogamicin given in combination with Enocitabine and Daunorubicin as induction therapy for elderly patients with acute myeloid leukemiaacute myeloid leukemiaJPRN-UMIN000002603Japan Adult Leukemia Study Group18